NPPA notifies 30% trade-margin cap on 137 anti-cancer drugs
The National Pharmaceutical Pricing Authority on 17 October 2026 notified an order capping trade margins at 30% on 137 non-scheduled anti-cancer drugs, invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013. Manufacturers must report revised prices within seven days; lower prices apply from 9 November. The NPPA estimates MRPs could fall by up to 70%.
Syllabus: GS2 · Statutory & Regulatory Bodies; GS2 · Government Policies; GS2 · Health, Education & Human Resources
Why this matters for UPSC
GS2 health policy and statutory bodies: Prelims can ask what Paragraphs 19 and 20 of the DPCO, 2013 provide, the NPPA's parent department and what the NLEM is; Mains, about medicine affordability and out-of-pocket spending.
Why it matters
A family paying for months of cancer treatment buys these medicines at the printed price, often from a hospital pharmacy. When the gap between what the maker charges and what the patient pays is wide, the family pays for that gap. Capping it means the same medicine should cost less at the counter from 9 November, while the maker's own earnings stay as they were. Cancer has long been among the illnesses that cost Indian households most from their own pockets and push many into borrowing. The larger question is how far the state should set prices for medicines outside the essential list without driving them off the shelves.
Prelims pointers
- NPPA: established by a Government of India Resolution dated 29 August 1997; it works under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- DPCO, 2013: issued under section 3 of the Essential Commodities Act, 1955; powers under several of its paragraphs, including Paragraph 19, are delegated to the NPPA.
- Paragraph 19, DPCO 2013: in extraordinary circumstances, if necessary in public interest, the Government may fix the ceiling or retail price of any drug for a period it deems fit.
- Paragraph 20, DPCO 2013: no manufacturer may raise any drug's MRP by more than 10% over the preceding twelve months; overcharges are repaid with interest plus penalty.
- Schedule-I of the DPCO is the NLEM; the NLEM 2022 has 388 drugs, 63 of them anti-cancer, all under price control, per the NPPA's order.
- Other uses of Paragraph 19 by the NPPA, per its own account: prices of 106 anti-diabetic and cardiovascular drugs, coronary stents and knee implants.
- Pharma Sahi Daam: the NPPA's online tool and app showing prices of scheduled and non-scheduled medicines, through which users can complain of overcharging.
Practise a UPSC-style question
With reference to the Drugs (Prices Control) Order, 2013, consider the following statements:
1. Its Paragraph 19 lets the Government fix the price of scheduled formulations, but not of non-scheduled formulations.
2. Under its Paragraph 20, a manufacturer may not raise a drug's MRP by more than ten per cent over the preceding twelve months.
Which of the statements given above is/are correct?
- (a) 1 only
- (b) 2 only
- (c) Both 1 and 2
- (d) Neither 1 nor 2
Show the answer
Answer: (b) 2 only
Answer: (b) 2 only. Paragraph 19 reaches any drug in extraordinary circumstances; Paragraph 20 caps a yearly MRP rise at 10%.
Statement 1: incorrect. Paragraph 19 lets the Government fix the ceiling or retail price of any drug in public interest; the NPPA used it in 2019 and in 2026 for non-scheduled cancer drugs.
Statement 2: correct. Paragraph 20 has the Government monitor the MRP of all drugs, non-scheduled formulations included, and bars a rise above 10% of MRP over the preceding twelve months.
Eliminate: Statement 1 is wrong, because the 137 drugs just capped under Paragraph 19 are all non-scheduled. Out: (a), (c).
Eliminate: Statement 2 gives the 10% limit of Paragraph 20 correctly. Out: (d).
Trap: Wrong scope. Statement 1 narrows the extraordinary power to scheduled drugs, when its use here is precisely to reach drugs outside the price-control list.
Remember: Paragraph 19 covers any drug in extraordinary circumstances; Paragraph 20 caps a non-scheduled MRP rise at 10% a year.
More from the 18 October 2026 edition
- Ethanol blending: 2026-27 tender shuts out sugar-based feedstocks Economy
- Deep magnitude-6.9 quake jolts Kamchatka on the Pacific Ring of Fire World & IR
- First tranche of India-US Bilateral Trade Agreement finalised, in legal drafting World & IR
- PRODES satellite survey puts Brazil's Amazon clearing at a series low Environment
- SEBI recasts Closing Auction Session; expiry settlement moves to VWAP Economy
- DGMA bars Indian seafarers from Sarawak's inland and coastal vessels National